You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Glaucos said Epioxa payer progress exceeded internal expectations and estimates 50,000 to 100,000 eyes are diagnosed with severe or progressive keratoconus.
Glaukos presented sales guidance for 2026 with a $1,000 million midpoint after 30 % topline growth in 2025, highlighting 14 disclosed pipeline programs and 12 currently commercialized products.
GLAUKOS Corp reported record third-quarter net sales of $211 million, up 58%, raised 2026 sales guidance to $775 to $785 million, and introduced preliminary 2027 revenue guidance of $1 billion. Non-GAAP gross margin reached approximately 88%.
GLAUKOS reported third-quarter net sales of $211.0 million, up 58%, and net income of $2.0 million. Nine-month net sales rose 50% to $547.2 million, while gross margin improved to 82% from 78%.
Glaukos reported record Q3 2026 net sales of $211.0 million, up 58%, raised 2026 net sales guidance to $775 million to $785 million from $680 million to $700 million, and introduced preliminary 2027 net sales guidance of $1 billion.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Glaukos reported record Q3 2026 net sales of $211.0 million, up 58%, raised 2026 sales guidance to $775 million-$785 million, introduced preliminary 2027 guidance of $1 billion, expanded gross margin, and strengthened profitability and cash generation as iDose TR and Epioxa scaled. Key risks include higher operating expenses, a year-to-date GAAP loss, potential iDose TR coverage restrictions, proposed ophthalmology fee reductions, and the time required to streamline Epioxa access and fund pipeline expansion.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GKOS
this stock
GLAUKOS Corp
|
$14.55B | +117.6% | +32.3% | — | 7.6% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Glaucos said Epioxa payer progress exceeded internal expectations and estimates 50,000 to 100,000 eyes are diagnosed with severe or progressive keratoconus.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GKOS | +9.5% | +49.1% | +113.7% | +3.4% | +117.6% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +6.9% | +50.2% | +113.2% | +3.6% | +107.0% |
